Sean Saint

And that was the advent of automated insulin delivery technologies.

They really started in the early 2010s and done nothing but gotten better to where we are today.

And of course, Betabionics represents the most recent and sort of the highest level of automation of what that is.

From my perspective, yes.

I mean, all of those things are important innovations, but the idea that we can respond to your blood sugar

in real time by increasing the insulin when you start to get high without you even knowing it's happening, by decreasing insulin when your blood sugar starts to get low automatically without you necessarily even know it's happening, that's really starting to take the burden off of the user.

And diabetes is a 24-7 unpaid job that you can't quit and you can't call in sick to.

So the real goal, what I think all of the companies are trying to accomplish is to reduce the burden of living with type 1.

We've taken different tacks in order to get there, but that ultimately is the end of the day, what we're really trying to do.

Better outcomes are fantastic, but better user experience of living with this disease is, I think, a goal that we don't want to forget about.

Yeah, so I would say there are two concepts that we want to keep in mind in order to understand that question.

The first is the way the user experiences the pump, right?

the sorts of interactions they need to have with it, how often they need to announce a meal, do they need to count their carbohydrates that they're eating, do they need to deliver correction boluses of insulin, do they need to extend their boluses of insulin, all these complicated concepts that with a traditional automated insulin delivery system they need to do.

And beta bionics is designed to eliminate most of those things.

We ask you to tell us that you're eating, but we don't require that you count carbs.

We don't require that you ever give a correction bolus.

Any of those other things I stated, not necessary with the islet.

So we're reducing the burden and the engagement required to really get a great outcome with our product.

And then sort of orthogonal to that is the burden on the healthcare provider.

Traditional automated insulin delivery systems require that the physician,